N2OFF, Inc. has announced an update to its ongoing acquisition of MitoCareX Bio Ltd. The company has amended the Securities Purchase and Exchange Agreement initially disclosed in February 2025. The amendment, dated May 18, 2025, extends the exclusivity period by an additional 90 days, allowing either party to terminate the agreement if the closing date does not occur within 180 days from the agreement's original date. This extension provides more time for N2OFF, Inc. to finalize the acquisition, which will result in MitoCareX becoming a wholly-owned subsidiary.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-012067), on May 22, 2025, and is solely responsible for the information contained therein.